What should you know?
Retatrutide is an investigational triple-agonist peptide designed to act on the GLP-1, GIP and glucagon receptors. It is currently being studied for its potential role in weight management and metabolic health. If your healthcare provider determines it is appropriate for you, treatment typically begins with a low dose that may be gradually increased under medical supervision.
Possible side effects
•Nausea
•Vomiting
•Diarrhea
•Constipation
•Headache
•Fatigue
•Dizziness
•Reduced appetite
•Reflux
•Other gastrointestinal symptoms.
Do not use with other GLP-1 medications or weight-loss injections unless directed by our medical team. Do not use if pregnant, breastfeeding, or trying to become pregnant.
Key information:
•Acts on GLP-1, GIP and glucagon receptors.
•Investigational therapy with potential effects on appetite, satiety and metabolic health.
•Once-weekly administration when prescribed by a healthcare professional.
•Requiresmedical evaluation and ongoing follow-up.
Important:
Retatrutide is an investigational peptide and is not approved by the U.S. Food and Drug Administration (FDA). Safety and effectiveness continue to be evaluated. A physician will review the potential risks, benefits, limitations and alternatives before treatment.
Restrictions apply. Adults 18 years of age or older only.
